Tempus AI

Tempus AI Operating Cash Flow

The Operating Cash Flow of Tempus AI (TEM) as of Oct 16, 2026 is -218.09 M USD. In the previous year, Operating Cash Flow was -189.05 M USD — a change of 15.36% (lower).

Operating Cash Flow

-218.09 MUSD

YoY

15.36%

Last updated:

Operating Cash Flow of Tempus AI is 2025 -218.09 M USD. Operating Cash Flow of Tempus AI was 2024 -189.05 M USD. It decreases by 15.36% lower compared to the previous year.

The Tempus AI Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
-117.11 M USD
Jan 1, 2020
-206.56 M USD
Jan 1, 2021
-211.98 M USD
Jan 1, 2022
-168.20 M USD
Jan 1, 2023
-214.34 M USD
Jan 1, 2024
-189.05 M USD
Jan 1, 2025
-218.09 M USD
The Tempus AI Operating Cash Flow history
YEAROperating Cash FlowYoY
-218.09 MUSD+15.36%
-189.05 MUSD-11.80%
-214.34 MUSD+27.43%
-168.20 MUSD-20.65%
-211.98 MUSD+2.62%
-206.56 MUSD+76.38%
-117.11 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc, listed on the stock market with ticker TEM and ISIN US88023B1035, is a U.S.-based company operating in the Health Care sector, specifically within the Life Sciences Tools & Services industry. Headquartered in Chicago, the company employs approximately 3,800 people. Tempus AI Inc completed its initial public offering (IPO) on June 14, 2024. The company's website is www.tempus.com. Tempus AI Inc provides next-generation diagnostics across multiple disease areas, utilizing data and analytics to support personalized medicine. Its product offerings include genomics, data analytics, and artificial intelligence applications. The genomics division operates laboratories that deliver next-generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and various anatomic and molecular pathology testing services. The AI applications division focuses on developing algorithmic diagnostics, software as a medical device, and clinical decision support tools. The company's primary AI platform, Next, uses machine learning to analyze routinely generated data, aiming to proactively identify and address care gaps for patients in oncology and cardiology. Tempus AI Inc is positioned as a technology company within the life sciences sector, leveraging advanced data capabilities to enhance medical care and treatment personalization. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Operating Cash Flow of Tempus AI is -218.09 M USD in 2025.

Operating Cash Flow of Tempus AI changed from -189.05 M USD to -218.09 M USD, representing a 15.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tempus AI

All Key Metrics — Tempus AI